Overall market performance

According to statistics, the total sales* of China’s hospital pharmaceutical market were RMB 187.2 billion in 2017 Q2, growing by 4.3% year on year. Based on 12-month MAT (Moving Annual Total*), the MAT growth of 2017 Q2 was 6.3%.

*Sales: Purchase amount of hospital pharmacies

* MAT (Moving Annual Total): The total of figures over the course of the previous 12 months from a designated time node. It means the sales over the course from 2016 Q3 to 2017 Q2 here.

 (Data source: China hospital drug statistical report of IMS, >=100 beds)

Market performance of multinational enterprises and Chinese enterprises

The 2017 Q2 sales growth of multinational enterprises was 9.4% in China, flat with the same period of last year, while that of Chinese enterprises was 2.7%, clearly down than the same period of last year. Pfizer, Yangtze River and AstraZeneca separately ranked the top three in enterprise quarterly sales rankings.

From the perspective of cities, the MAT growth of multinational enterprises and Chinese enterprises was separately 7.4% and 8.5% in first-tier cities, while the MAT growth thereof was separately 12.7% and 6.7% in small and medium-sized cities.

First-tier cities: Beijing, Shanghai, and Guangzhou

Market performance of key therapeutic areas and major products

From the perspective of therapeutic areas, antineoplastic drugs and immunomodulators, and respiratory system drugs maintained some growth in this quarter, while the growth of Chinese patent medicines and anti-infectives continued to slow down due to use restriction of adjuvant drugs and further strengthening of antibiotic drug clinical application management, etc.

From the perspective of products, the multinational enterprise’s Lipitor ranked top in the 2017 Q2 product sales rankings, the Chinese enterprise’s Jialuoning ranked second, and Plavix ranked third. From the perspective of MAT growth, Jialuoning and Sulperazon separately reached 29.3% and 28.4%, while other products fluctuated in terms of the growth, but did not change much in the rankings.

Top 10 Hospital Pharmaceutical Product Suppliers in China in 2017 Q2 (by Quarterly Sales)

Top 10 Therapeutic Areas in Hospital Drug Use in 2017 Q2 (by Quarterly Sales)

Data source: IMS CHPA (China hospital drug statistical report), >=100 beds

Top 10 Products in Hospital Drug Use in 2017 Q2 (by Quarterly Sales)

Data source: IMS CHPA (China hospital drug statistical report), >=100 beds

Also read: Review of Drug Use on Hospital Market in China in 2017 Q3

Register as Visitor to CPhI China 2018!